Cellectis Reports First Quarter 2022 Financial Results and Business Update
Cellectis announced its first quarter 2022 financial results and business update, reporting $142 million in cash as of March 31, 2022. The company also received a $20 million convertible note.
New York, NY – May 12, 2022 – Cellectis, a clinical-stage biotechnology company focused on gene-editing technologies for cell and gene therapies, has released its financial results for the first quarter ended March 31, 2022. The company reported a cash position of $142 million as of the end of the quarter.
During the first quarter, Cellectis presented preclinical data for its UCART20x22 product candidate, demonstrating proof-of-concept with robust anti-tumor activity for the allogeneic dual CAR T-cell therapy being developed for relapsed or refractory non-Hodgkin’s lymphoma (NHL). Additionally, the company published two articles in Nature Communications validating its UCART123 candidate for treating acute myeloid leukemia (AML) and B-cell lymphoproliferative disorders (BPDCN).
Cellectis also received a $20 million convertible note as part of a collaboration agreement with its partner Cytovia Therapeutics. In a separate development, the U.S. Food and Drug Administration (FDA) allowed an Investigational New Drug (IND) application to proceed for Iovance Biotherapeutics’ first genetically modified TIL therapy, which utilizes Cellectis' TALEN® gene editing technology.
The company continues to advance its pipeline of cell therapies aimed at treating serious diseases, with upcoming clinical studies and ongoing collaborations forming key aspects of its future development strategy.